Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemtuzumab Ozogamicin Makes a Comeback

    Cancer Discovery
    |September 22, 2017
    PubMed
    Summary

    Gemtuzumab ozogamicin, a CD33-targeting antibody-drug conjugate, is now FDA-approved for newly diagnosed acute myeloid leukemia and relapsed/refractory disease in patients aged 2 and older. It can be administered alone or with chemotherapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

    Cancer discovery·2026
    Same journal

    Nonprofit Acquires Abandoned Leukemia Drug Supply.

    Cancer discovery·2026
    Same journal

    Limited Deoxynucleoside Pools Underlie Cisplatin-Induced Neurotoxicity.

    Cancer discovery·2026
    Same journal

    Chemically Induced Skin Tumors Arise from Upper Hair Follicle Stem Cells.

    Cancer discovery·2026
    Same journal

    Retraction Casts Doubt on Timing Effects of Immunotherapy.

    Cancer discovery·2026
    Same journal

    mtDNA Lineage Tracing Reveals Monocyte Fate Bias Prior to Tumor Infiltration.

    Cancer discovery·2026

    Area of Science:

    • Hematology
    • Oncology
    • Pharmacology

    Background:

    • Gemtuzumab ozogamicin was previously withdrawn from the market.
    • Acute myeloid leukemia (AML) remains a significant challenge in hematologic oncology.
    • Targeted therapies are crucial for improving AML treatment outcomes.

    Purpose of the Study:

    • To report the reapproval of gemtuzumab ozogamicin by the FDA.
    • To outline the new indications for gemtuzumab ozogamicin in AML treatment.

    Main Methods:

    • The study focuses on regulatory approval and drug indications.
    • Review of FDA decisions and drug labeling for gemtuzumab ozogamicin.

    Main Results:

    • Gemtuzumab ozogamicin has received FDA reapproval.
    • The drug is indicated for adults with newly diagnosed AML.
    • It is also approved for patients aged 2 years and older with relapsed/refractory AML.

    Conclusions:

    • Gemtuzumab ozogamicin offers a new therapeutic option for various AML patient populations.
    • The antibody-drug conjugate can be used as a monotherapy or in combination regimens.

    Related Experiment Videos